What Fostimon Treats: Main Uses and Benefits

Fostimon is considered relevant across domains where additional symptomatic support is needed in contexts involving heightened systemic burden related to reproductive function. It is commonly used for managing symptoms related to systemic imbalance and symptoms linked to organ-specific functional stress.

Fostimon is commonly used across conditions presenting with acute episodes. This may include scenarios where symptoms become temporarily overwhelming, such as in women with anovulation (including those with Polycystic Ovarian Syndrome, PCOS), and when supportive relief is needed prior to Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF).

Fostimon may assist with maintaining a sense of stability when symptoms are more noticeable. It provides support that helps ease the overall symptom burden, and is commonly used to help with symptom clusters that may become intense or disruptive, relevant in contexts involving heightened systemic burden.

---

Quick Fact: Supports Symptoms that Interfere with Daily Functioning

Regulatory References

1. EMA Patient Information

Official Eligibility and Contraindications

The eligibility for Fostimon (urofollitropin) is strictly defined by regulatory documents, allowing its use primarily in Adult Women undergoing fertility treatment for anovulation (including PCOS patients unresponsive to clomiphene citrate) or for Controlled Ovarian Stimulation during Assisted Reproductive Technologies (ART).

---

Populations for Whom Use is Contraindicated

Fostimon is formally contraindicated and must not be used in patients with the following conditions:

• Active Tumors of the breast, uterus, ovary, hypothalamus, or pituitary gland.
• Primary Ovarian Failure, typically indicated by high endogenous Follicle-Stimulating Hormone (FSH) levels, as a successful response is not expected.
• Ovarian Cysts or enlargement not caused by polycystic ovarian disease (PCOS).
• Abnormal Uterine Bleeding of unknown origin, or severe structural malformations of the sexual organs that prohibit normal pregnancy.
• Hypersensitivity (allergy) to urofollitropin or any of the product's excipients.

Restricted and Non-Established Use

Use is also contraindicated during Pregnancy and Lactation (Breastfeeding). Caution and careful assessment are required for women with recognized risk factors for thrombosis, such as a personal or family history of blood clots or severe obesity (BMI > 30 kg/ m^2). Regulatory authorities note that safety and efficacy have not been established in the pediatric or geriatric populations.

Fostimon Interactions with other medicines and products

This section outlines the officially documented interaction profile of Fostimon (urofollitropin), based strictly on government regulatory information.

---

Documented Pharmacodynamic Interactions

Interactions involving an enhanced therapeutic effect are documented in regulatory labeling. The co-administration of Clomifene Citrate is expected to enhance the follicular response to Fostimon. This effect is classified as a pharmacodynamic reinforcement of the follicle-stimulating action.

---

Conditional Restrictions on Co-Administration

Interacting Substance	Restriction Context
Human Chorionic Gonadotropin (hCG)	Administration must be withheld if ovarian monitoring on the last day of Fostimon treatment indicates an increased risk of Ovarian Hyperstimulation Syndrome (OHSS).

This restriction is a specific procedural requirement tied to clinical monitoring and is not a general prohibition.

---

Absence of Documented Pharmacokinetic Interactions

Official regulatory documentation notes that no dedicated drug-drug interaction studies have been conducted for Fostimon in humans. Consequently, there is no official documentation regarding:**

• Metabolic Interactions: No documented interactions involving CYP enzymes or other metabolic pathways.
• Exposure Alterations: No substances are documented to increase or decrease Fostimon plasma levels (AUC/Cmax).
• Food/Products: No interactions with food, alcohol, supplements, or herbal products are explicitly stated in the prescribing information.

Fostimon is a preparation of highly purified Urofollitropin (Follicle-Stimulating Hormone, FSH) isolated from human postmenopausal urine. Upon systemic administration, the exogenous FSH glycoprotein hormone targets the gonads—specifically the granulosa cells within the ovarian follicles in females. It acts as an agonist at the cell surface-expressed FSH receptor (FSHR), a G protein-coupled receptor (GPCR) predominantly coupled to the G s heterotrimeric protein .

Ligand binding activates the FSHR, initiating a downstream signaling cascade. The activated G s subunit stimulates adenylyl cyclase (AC), catalyzing the conversion of ATP to cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP levels serve as the second messenger, activating Protein Kinase A (PKA). PKA then phosphorylates target proteins and transcription factors, leading to changes in gene expression, notably those involved in steroidogenesis and cellular proliferation. The system-level consequence is the modulating of follicular maturation within the ovary, promoting the growth and development of the ovarian follicles through direct cellular stimulation.

How Fostimon is Used: Official Administration Guidelines

Fostimon (urofollitropin) is administered via injection according to specific, highly individualized protocols outlined in official prescribing information. The dosage and duration are determined by a physician based on the patient's ovarian response, which is continually monitored through ultrasound and estradiol levels.

---

Administration and Preparation

Fostimon is supplied as a powder and solvent for solution for injection. It is approved for Subcutaneous (SC) or Intramuscular (IM) administration. The powder must be reconstituted immediately before use with the provided solvent under aseptic conditions; the vial should be gently rolled to dissolve the powder, and not shaken. While SC injections may be self-administered after proper training, the first injection must be performed under direct medical supervision.

---

Standard Dosing Regimens

Dosing is a daily, stepwise process. Dosage units are measured in International Units (IU) of Follicle-Stimulating Hormone (FSH).

Treatment Goal	Typical Starting Dose (Daily)	Typical Maximum Dose (Daily)
Ovulation Induction	75 IU to 150 IU	Generally 225 IU
ART/Superovulation	150 IU to 225 IU	Generally 450 IU

---

Treatment Schedule and Completion

Fostimon is administered once per day. Dose adjustments, typically in increments of 37.5 IU to 75 IU, occur at intervals of 7 or 14 days to achieve the desired effect. The course of daily injection usually lasts for 7 to 14 days. Following the final Fostimon dose, a single injection of human chorionic gonadotropin (hCG) (typically 5,000 to 10,000 IU) is administered 24 to 48 hours later to conclude the procedural sequence. Official documentation does not provide specific dosing adjustments for pediatric, renal, or hepatic impairment populations.

Research evidence / Overview of studies for Fostimon

Evidence for use in Ovulation Induction

This section will summarize the clinical trials and research studies that have examined Fostimon in women who have conditions characterized by fluctuating or episodic manifestations that prevent or disrupt regular ovulation. Fostimon was studied in research exploring ovulation in women with certain systemic or functional imbalances. It will outline the types of studies that exist regarding outcomes such as ovulation and conception in this group.

The research was evaluated in settings that focus on outcomes related to systemic or functional imbalance, such as whether ovulation occurred and if pregnancies followed. Studies report how outcomes evolved in the observed populations, and the findings describe patterns related to outcomes such as ovulation and pregnancy in some women.

It is important to understand that research results apply only to the populations studied. While certain changes were measured during the study period, certainty remains low for predicting individual success. Furthermore, comparative evidence is lacking in some areas, meaning we have limited information directly comparing Fostimon to all other available interventions.

---

Evidence for use in Controlled Ovarian Hyperstimulation (COH) for ART

This part of the section reviews the research where Fostimon was observed in women preparing for Assisted Reproductive Technology (ART) procedures, such as IVF. In these studies, research examined Fostimon's evaluation in follicular development.

The outcomes related to systemic or functional imbalance that studies monitored included follicular development, the quality of the embryos developed, and the rate of live births. Findings indicate that research describes how Fostimon was evaluated to promote follicular development as part of an ART cycle. This research highlights outcomes measured during the study period, but it does not determine whether an individual will respond similarly.

Studies explored how the level of ovarian response may vary between individuals. It is crucial to note that follow-up durations were limited in many of these trials. There is limited information for long-term outcomes for all outcomes. This evidence provides context but not individual predictions regarding the success of an ART cycle.

---

Long-term studies and follow-up

This section will summarize what research describes about longer-term outcomes for women who have received fertility interventions using Fostimon, as well as the children born from these interventions. Studies monitored for any health outcomes that may only become noticeable over an extended time.

The available research provides context on what was associated with the intervention during the study period, but evidence is limited regarding outcomes many years after the intervention. There is limited information for long-term outcomes, and data are still emerging regarding the durability of response and any extended-duration health information for women or their children. This area of research is ongoing to provide more insight into extended health outcomes.

---

Evidence in special populations

This part will outline what studies have evaluated Fostimon in specific groups, such as those with certain health concerns or where data for certain groups remain insufficient. For instance, research examined outcomes in women who have been identified as having either a high or low likelihood of responding to ovarian stimulation. Research provides insight into short-term changes in these subgroups, but often the sample sizes were modest, meaning the results are based on a smaller number of people. Consequently, subgroup findings are uncertain, and results may not be as reliable as those from larger studies focused on the general population seeking fertility interventions.

---

What is still uncertain about Fostimon

This section synthesizes the main evidence gaps and areas where more research is still needed. Although Fostimon has been studied for its approved uses, there are areas where the evidence remains unclear or where different studies have produced conflicting results. For example, findings were mixed when comparing Fostimon head-to-head against some other similar medications in certain outcomes, and the best way to use the medication in all scenarios is still uncertain. This research highlights what is known—and what is still uncertain—about Fostimon.

Key Studies & References Guideline: Use of ovulation induction agents (American Society for Reproductive Medicine, ASRM)

Common questions about Fostimon (FAQ)

Q: Do you always have to mix Fostimon before use?

A: Yes. Fostimon is supplied as a powder and a separate solvent (liquid). Official product information states the powder must be mixed, or reconstituted, with the provided solvent immediately before administration.

Q: What is the difference between Fostimon and other fertility shots?

A: Fostimon contains the active substance urofollitropin, a form of Follicle-Stimulating Hormone (FSH). Official regulatory information notes that Fostimon is highly purified and is derived from human postmenopausal urine, distinguishing it from synthetic FSH products.

Q: How quickly does Fostimon start working after the first injection?

A: Following an injection, the maximum concentration of the active substance in the blood is typically reached within a few hours. The overall treatment involves daily injections over several days to support the biological process of follicular growth.

Q: Does Fostimon interact with common pain relievers like ibuprofen?

A: Official regulatory documentation states that dedicated drug-drug interaction studies have not been conducted with Fostimon in humans. Patients should consult with their prescribing physician regarding all concurrent medications.

Q: Are there any foods or supplements that should be avoided with Fostimon?

A: No official regulatory documentation explicitly states interactions with food, alcohol, or supplements. Patients should inform their prescribing physician about all supplements and products being used.

Q: Can Fostimon be used in women who are older than 40?

A: Fostimon is indicated for use in adult women undergoing fertility treatment. However, official regulatory documents note that the safety and effectiveness of the medication have not been established in the geriatric population, which requires careful clinical consideration.

Q: Is Fostimon known to cause headaches?

A: Yes, headache is listed in official regulatory documents as a common side effect of Fostimon.

Q: Is Fostimon used to treat Polycystic Ovary Syndrome (PCOS)?

A: Fostimon is officially indicated for the treatment of anovulation (the absence of ovulation). This includes women with Polycystic Ovarian Disease (PCOD) who have been unresponsive to treatment with clomifene citrate.

Q: Can Fostimon be used with other fertility drugs in the same cycle?

A: Yes, regulatory documentation notes that co-administration with clomifene citrate may enhance the follicular response. The administration of human chorionic gonadotropin (hCG) is also a standard procedural step in the treatment regimen.

Q: Is Fostimon linked to a higher risk of certain cancers?

A: Fostimon is contraindicated (must not be used) in patients with active cancers of the reproductive organs. Official warnings note that tumors of the reproductive system have been reported in women receiving infertility treatments, but a definitive causal link to gonadotrophin treatment has not been established.

Q: Can Fostimon cause mood swings or emotional changes?

A: Changes in mood or emotional state are listed in official documents as an uncommon side effect of Fostimon.

Q: Is it normal to feel bloated while taking Fostimon?

A: Yes, abdominal bloating or discomfort is listed in official documents as a common side effect of Fostimon. Bloating can also be a symptom of Ovarian Hyperstimulation Syndrome (OHSS); a physician monitors for signs of this condition during treatment.

Q: What happens if a dose of Fostimon is missed?

A: Regulatory patient information advises contacting the prescribing physician or fertility clinic immediately if a dose of Fostimon is missed. Regulatory patient information does not provide instructions for self-adjusting the dose.

Q: Can I travel with Fostimon injections?

A: Official storage requirements describe keeping the powder in the original packaging to protect it from light and storing it at a temperature not above 25 C (77 F) before reconstitution.

Q: Why do some people need Fostimon for multiple days?

A: The medication is administered daily to provide the necessary, continuous hormonal support. This continuous administration is needed because the growth and development of ovarian follicles, which Fostimon stimulates, is a natural, multi-day biological process.

Q: How long does Fostimon stay in your system?

A: The elimination half-life of the active ingredient, urofollitropin, which measures how long it takes for half of the substance to be eliminated, is generally reported in official documents to be approximately 35 to 40 hours.

Q: What is the typical monitoring schedule (blood tests, ultrasounds) while on Fostimon?

A: The official instructions emphasize that ovarian response must be continually monitored by a physician. This is done using ultrasound examination and by measuring estradiol levels, with the schedule determined by the individual patient's clinical response.

Q: Does Fostimon contain any animal products?

A: The active substance, urofollitropin, is officially derived from human postmenopausal urine. The full composition, including all excipients (inactive ingredients), is detailed in the official product information.

Q: What is the research evidence for using Fostimon in women with low ovarian reserve?

A: Clinical data related to women identified as having a low likelihood of response to ovarian stimulation is available in research summarized in the official documentation. This research helps inform physicians about potential outcomes in this specific group.

Q: What should I expect after taking Fostimon?

A: The medication is intended to stimulate follicular development in the ovaries. Expected effects are physical, and common side effects, such as headache, pelvic pain, or abdominal bloating, are listed in the product information.

Q: Can Fostimon cause changes in appetite or weight?

A: Weight gain is listed in official documents as an uncommon side effect of Fostimon.

Q: Is it common to feel fatigued while taking Fostimon?

A: Fatigue (tiredness) is listed in official documents as an uncommon side effect of Fostimon.

Q: Are there reports of allergic reactions to Fostimon?

A: Hypersensitivity reactions are listed as possible side effects in official documents. Furthermore, a known hypersensitivity (allergy) to the active substance or excipients is a contraindication for use.

Q: Does Fostimon require a long treatment period?

A: The course of daily Fostimon injections typically lasts for 7 to 14 days. The exact duration is determined by a physician based on the patient's clinical response and continuous monitoring.

How to Store and Dispose of Fostimon?

Fostimon (urofollitropin) must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.

Official Storage Requirements

Storage Component	Official Requirement
Temperature	Store not above 25 C before reconstitution.
Light Protection	Keep in the original package (outer carton) to protect from light.
Post-Reconstitution	The solution for injection must be used immediately after preparation.
Child Safety	Keep this medicine out of the sight and reach of children.

Expiration and Disposal

Do not use Fostimon after the expiry date printed on the carton, vial, and solvent ampoule. Once prepared, any solution that is not used immediately must be discarded. All unused medicinal product and waste material must be disposed of in accordance with local requirements.